ApoGen increases 2016 Series A funding round to $11 million
Company draws $4 million in additional funding from Merck KGaA's venture capital arm and other investors.
Company draws $4 million in additional funding from Merck KGaA's venture capital arm and other investors.
Company seeks to block components of reactivated programmed cell death process implicated in Alzheimer's disease.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.